RSS   Newsletter   Contact   Advertise with us
Post Online Media

Syndax appoints Richard Shea chief financial officer

Syndax PharmaceuticalsSyndax Pharmaceuticals, a clinical stage biopharmaceutical company, announced that Richard P. Shea is stepping down from his position on the Syndax board of directors and is joining the company as CFO, effective February 13, 2017.
Mr. Shea has more than 30 years of experience in a range of financial and advisory roles in the biotechnology industry, most recently serving as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals, Inc. as well as the chair of the Audit Committee of Syndax's Board of Directors.

Before being named Senior Vice President and Chief Financial Officer of Momenta in July 2007, Mr. Shea served as its Vice President and Chief Financial Officer since October 2003.

Prior to joining Momenta, he served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc.

Mr. Shea received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University.

Upon the effective date of his appointment as the Company's Chief Financial Officer, Mr. Shea will resign from his positions as a member of Syndax's Board of Directors and as Chair of the Audit Committee of the Board of Directors.

The Company's Board of Directors has elected Pierre Legault as the Chair of the Audit Committee to replace Mr. Shea.


 LATEST MOVES FROM Massachusetts 


POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.